Associations - Besponsa (inotuzumab ozogamicin)

CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria inotuzumab ozogamicin Sensitive : C2	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria inotuzumab ozogamicin Sensitive : C2
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
MLL rearrangement	Acute Lymphocytic Leukemia	MLL rearrangement	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3
MLL rearrangement	Acute Lymphocytic Leukemia	MLL rearrangement	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3
TP53 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3
TP53 mutation + IKZF3 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation + IKZF3 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
TP53 mutation + IKZF1 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation + IKZF1 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
IKZF3 mutation	B Acute Lymphoblastic Leukemia	IKZF3 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
TP53 deletion	B Acute Lymphoblastic Leukemia	TP53 deletion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
IKZF1 mutation	B Acute Lymphoblastic Leukemia	IKZF1 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
TP53 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CD22 overexpression	Acute Lymphocytic Leukemia	CD22 overexpression	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CD22 underexpression + BCL2 overexpression	Acute Lymphocytic Leukemia	CD22 underexpression + BCL2 overexpression	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3
CRLF2 overexpression	B Acute Lymphoblastic Leukemia	CRLF2 overexpression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CRLF2 overexpression	B Acute Lymphoblastic Leukemia	CRLF2 overexpression	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Sensitive : C3	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Sensitive : C3
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CD58 expression	B Acute Lymphoblastic Leukemia	CD58 expression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3

Besponsa (inotuzumab ozogamicin)

Associations
(28)

Associations
(28)

Besponsa (inotuzumab ozogamicin)

Associations(28)

Associations(28)

Associations
(28)

Associations
(28)